Cetus Corp. on Tuesday declined to comment on reports that itsinterleukin-2 for renal cell carcinoma will be reviewed by aFood and Drug Administration advisory committee this July.

Cetus stock (NASDAQ:CTUS) closed up $1.38 on Tuesday at$16.38 after Dr. Steven Rosenberg, chief of surgery at theNational Cancer Institute, told attendees at the AmericanSociety of Clinical Oncology meeting in Houston that IL-2 willbe on the FDA's July agenda.

Rosenberg, who made the comment Monday upon receiving theKarnofsky Award for his work on gene therapy andimmunotherapy to treat cancer, could not be reached byBioWorld.

"Steve did say that in his presentation," said Jana Cuiper,spokeswoman for the Emeryville, Calif., company. "ButRosenberg doesn't speak for Cetus."

An FDA spokeswoman said it will probably be several weeksbefore the agency's July schedule is completed.

Last July, the FDA's bioresponse modifiers committee delayedits recommendation on Cetus' IL-2, instead asking for moreclinical data.

(c) 1997 American Health Consultants. All rights reserved.

No Comments